John Callahan, a partner in its Washington, D.C. office of Sughrue Mion, was a key speaker at a six-day workshop in India attended by leading Indian pharmaceutical companies. The program focused on a range of topics and best practices including patent litigation, patent infringement, inventors’ rights, U.S. patent office procedure, licensing issues and the World Trade Organization (WTO) Agreement on Trade-Related Intellectual Property Rights (TRIPs). The event was presented by the Technology Information Forecasting & Assessment Council (TIFAC) and the Institute of Intellectual Property Research & Practice.
“Patent protection and patent enforcement are major issues for pharmaceutical manufacturers and developers in India. And being able to sell drugs to U.S. consumers requires a detailed understanding of U.S. patent laws,” said Mr. Callahan. “The fact that so many professionals spent six days getting an overview of patent processes and applications makes it clear that these companies are taking these issues very seriously.”
The conference came on the heels of major changes to India’s own pharmaceutical patent laws. The debates surrounding these new laws bring patents to the forefront in India. Currently India has a $10 billion pharmaceutical industry and is fourth largest producer of pharmaceuticals in the world, based on volume.
“India is poised to be the worldwide hub for pharmaceutical R&D,” said Mr. Amar Raj Lall, President of the Institute of Intellectual Property Research & Practice. “To tap into the U.S. market, which is the world’s largest pharmaceutical market in terms of dollars, we felt this workshop was important to help Indian companies properly protect their intellectual property as they reach new markets.”
Presenting with Mr. Callahan were Dr. Thomas D. Paul of Fulbright & Jaworski, LLP, and Mr. Clifford Mass and Mr. John Richards of Ladas & Parry.